Sandoz Group AG

Equities

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:02 2024-06-28 am EDT 5-day change 1st Jan Change
32.54 CHF -0.97% Intraday chart for Sandoz Group AG -0.73% +20.25%
LockThis article is for Premium subscribers only
SUBSCRIBE to Premium to unlock this high value-added content!
Already a customer? Log In

The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on SANDOZ GROUP AG since 2024-06-24 .

Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA CI
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement MT
Swiss Market Index Closes Higher; Sandoz Gains MT
SANDOZ : Sandoz’s improvements are worth betting on Alphavalue
SANDOZ : Q1 miss not a worry; expect another boost for the share price Alphavalue
Sandoz: 5% sales growth in Q1 CF
Europe rises, buoyed by financial results RE
Transcript : Sandoz Group AG, Q1 2024 Sales/ Trading Statement Call, May 07, 2024
Sandoz Group Logs Growth in Q1 Net Sales, Affirms FY24 Outlook MT
Sandoz Announces Sales Results for the First Quarter 2024 CI
Sandoz Group Ag Reiterates Earnings Guidance for the Full Year 2024 CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla... Our Logo
Sandoz Group AG Announces Appointment of Graeme Pitkethly as Non-Executive Director and Chair of Its Audit, Risk and Compliance Committee CI
Sandoz Group AG Announces Board and Committee Appointments CI
Sandoz Group AG Approves Dividend, Payable on May 7, 2024 CI
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation DJ
Sandoz Group Settles Patent Disputes with Amgen MT
Sandoz reaches agreement with Amgen over patent dispute RE
Cigna to offer Humira rivals with $0 copay at specialty pharmacy RE
Swiss Market Index Closes Higher; UBS Slumps MT
Chart Sandoz Group AG
More charts
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
36.21 USD
Average target price
40.41 USD
Spread / Average Target
+11.59%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SDZ Stock
  4. News Sandoz Group AG
  5. Sandoz: Ready to unleash its full potential on its own